Jiangsu Recbio Technology Co., Ltd. (SEHK: 2179)
Health Care · Biotechnology · CN
HK$4.42
+0.23% today · -35.0% 1Y
Jiangsu Recbio Technology Co., Ltd. (SEHK: 2179) operates in the Biotechnology industry within the Health Care sector. The company is valued at $347.01M and employs 491 people.
Over the last twelve months the share price has lost 35.0%, trading between 3.40 and 7.20.
Tweenvest scores Jiangsu Recbio Technology Co., Ltd. across four factors: quality 32/100, value 51/100. Its strongest factor is value.
2179 price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $347.01M
- Revenue (TTM)
- $72.43K
- P/E
- —
- EPS
- -0.80
- Dividend yield
- —
- Beta (5Y)
- 0.13
- 52-week high
- HK$7.20
- 52-week low
- HK$3.40
- Avg volume (3M)
- —
- Shares outstanding
- 616.81M
- Employees
- 491
- Next earnings
- —
About Jiangsu Recbio Technology Co., Ltd.
Jiangsu Recbio Technology Co., Ltd. operates as a biotechnology company primarily engaged in the pioneering research, development, and eventual market introduction of subunit vaccines throughout the People's Republic of China. A significant portion of its pipeline is dedicated to combating human papillomavirus (HPV)-related diseases, including cervical cancer and genital warts. Its most advanced candidate, REC603, is a recombinant 9-valent HPV vaccine currently undergoing Phase III clinical trials. Additionally, two bivalent HPV vaccines, REC601 and REC602, are progressing through Phase I trials. Further early-stage development includes the quadrivalent REC604a and 9-valent REC604b recombinant HPV vaccines, both in preclinical stages. Beyond HPV, the company boasts a diverse pipeline addressing other infectious diseases. Its COVID-19 efforts include ReCOV, a recombinant vaccine candidate in Phase II/III trials, and the preclinical messenger RNA (mRNA) candidate, R520A. Other preclinical projects target various conditions, such as the recombinant shingles vaccine REC610, the virus-vectored adult tuberculosis vaccine REC607, and its recombinant counterpart REC606. Also in preclinical development are the recombinant quadrivalent influenza vaccine REC617 and the recombinant quadrivalent hand-foot-mouth disease vaccine REC605. Established in 2011, Recbio Technology maintains its headquarters in Taizhou, People's Republic of China.
- ISIN
- CNE1000057K9
- Founded
- 2011
- Listed since
- Mar 31, 2022
- Exchange
- The Stock Exchange of Hong Kong Ltd.
- Currency
- HKD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Jiangsu Gdk Biological Technology Co., LtdSHSE: 688670 | $352.60M | CN¥19.17 | +2.35% |
| BioDlink International Company LimitedSEHK: 1875 | $350.57M | HK$3.56 | -4.30% |
| Surrozen, Inc.NasdaqCM: SRZN | $348.96M | $29.69 | +1.26% |
| BioNote, Inc.KOSE: A377740 | $348.29M | ₩4,640.00 | -1.28% |
| ROKIT Healthcare Inc.KOSDAQ: A376900 | $346.80M | ₩26,850.00 | -3.24% |
| Agenus Inc.NasdaqCM: AGEN | $345.31M | $7.67 | +1.72% |
| Artiva Biotherapeutics, Inc.NasdaqGM: ARTV | $339.30M | $6.94 | +2.06% |
| Indaptus Therapeutics, Inc.NasdaqCM: INDP | $334.44M | $2.51 | +5.46% |
Figures last refreshed Oct 11, 2026.